Enfortumab vedotin is an antibody–drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacri-mation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedo-tin. Enfortumab vedotin is not previously known to cause cataract development or progres-sion and, thus, our patient’s presentation may reflect the first report of an undocumented adverse effect of this novel agent.
CITATION STYLE
Thibodeau, A., & Nallasamy, N. (2021). Bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. International Medical Case Reports Journal, 14, 707–709. https://doi.org/10.2147/IMCRJ.S324394
Mendeley helps you to discover research relevant for your work.